Systemic antifungal therapy in critically ill patients without invasive fungal infection*

Critical Care Medicine

Volumn 40, Issue 3, 2012, Pages 813-822

  Azoulay, Elie ^a,b   Dupont, Hervé ^c   Tabah, Alexis ^b,d   Lortholary, Olivier ^a,e,f   Stahl, Jean Paul ^g   Francais, Adrien ^b,d   Martin, Claude ^h   Guidet, Bertand ⁱ   Timsit, Jean François ^b,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d Michallon Teaching Hospital   (France)

^e INSTITUT PASTEUR   (France)

^f CNRS   (France)

^g HÔPITAL MICHALLON   (France)

^h HÔPITAL NORD   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

Author keywords

acute respiratory failure; candidemia; colonization; mechanical ventilation; organ failure

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADULT; AGED; ARTICLE; CANDIDA; CANDIDEMIA; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; FUNGAL COLONIZATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; SEPSIS; SYSTEMIC MYCOSIS;

AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COHORT STUDIES; CRITICAL ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84857648821     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318236f297     Document Type: Article

References (39)

1. Blumberg HM, Jarvis WR, Soucie JM, et al: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33:177-186
2. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al: National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-258
3. Wisplinghoff H, Bischoff T, Tallent SM, et al: Nosocomial bloodstream infections in US hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317
4. Pittet D, Li N, Woolson RF, et al: Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model. Clin Infect Dis 1997;24:1068-1078
5. Garrouste-Orgeas M, Timsit JF, Tafflet M, et al: Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: A reappraisal. Clin Infect Dis 2006;42:1118-1126
6. Vincent JL, Rello J, Marshall J, et al: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-2329
7. Pittet D, Monod M, Suter PM, et al: Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-758
8. Eggimann P, Garbino J, Pittet D: Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702
9. Leon C, Ruiz-Santana S, Saavedra P, et al: Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. Crit Care Med 2009;37:1624-1633
10. Ostrosky-Zeichner L, Pappas PG: Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857-863
11. Garey KW, Rege M, Pai MP, et al: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006;43:25-31
12. Labelle AJ, Micek ST, Roubinian N, et al: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008;36:2967-2972
13. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of candida blood-stream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-3645
14. San Miguel LG, Cobo J, Otheo E, et al: Secular trends of candidemia in a large tertiarycare hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005;26:548-552
15. Marchetti O, Bille J, Fluckiger U, et al: Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-320
16. Playford EG, Webster AC, Sorrell TC, et al: Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: Systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006;57:628-638
17. Cruciani M, de Lalla F, Mengoli C: Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: A systematic review and meta-analysis. Intensive Care Med 2005;31:1479-1487
18. Shorr AF, Chung K, Jackson WL, et al: Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis. Crit Care Med 2005;33:1928-1935; quiz 1936
19. Pelz RK, Hendrix CW, Swoboda SM, et al: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-548
20. Jacobs S, Price Evans DA, Tariq M, et al: Fluconazole improves survival in septic shock: A randomized double-blind prospective study. Crit Care Med 2003;31:1938-1946
21. Garbino J, Lew DP, Romand JA, et al: Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002;28:1708-1717
22. Piarroux R, Grenouillet F, Balvay P, et al: Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004;32:2443-2449
23. Schuster MG, Edwards JE Jr, Sobel JD, et al: Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med 2008;149:83-90
24. Montravers P, Dupont H, Gauzit R, et al: Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006;34:646-652
25. Leroy O, Gangneux JP, Montravers P, et al: Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009;37:1612-1618
26. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al: Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997;23:23-30
27. Lam S, Eschenauer G, Carver P: Evolving role of early antifungals in the adult intensive care unit. Crit Care Med 2009;37:1580-1593
28. Pappas PG, Kauffman CA, Andes D, et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535
29. De Pauw B, Walsh TJ, Donnelly JP, et al: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821
30. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963
31. Pollack MM, Ruttimann UE, Getson PR: Pediatric Risk of Mortality (PRISM) score. Crit Care Med 1988;16:1110-1116
32. Mounier R, Adrie C, Francais A, et al: Study of prone positioning to reduce ventilator associated pneumonia in hypoxaemic patients. Eur Respir J 35:795-804
33. Klein M, Postma TJ, Taphoorn MJ, et al: The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 2003;61:1796-1798
34. Vardakas KZ, Michalopoulos A, Kiriakidou KG, et al: Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients. Clin Microbiol Infect 2009;15:289-292
35. Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001;32:1191-1200
36. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, et al: Risk factors for fluconazoleresistant candidemia. Antimicrob Agents Chemother 2010;54:3149-3154
37. Leroy O, Mira JP, Montravers P, et al: Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010;14:R98
38. Chow JK, Golan Y, Ruthazer R, et al: Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008;36:1993-1998
39. Leon C, Ruiz-Santana S, Saavedra P, et al: A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34:730-737